Literature DB >> 9922308

Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

G Cadiot1, A Vuagnat, I Doukhan, A Murat, G Bonnaud, B Delemer, G Thiéfin, A Beckers, M Veyrac, C Proye, P Ruszniewski, M Mignon.   

Abstract

BACKGROUND & AIMS: Risk factors of metachronous liver metastases and death are not well known in patients with the Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. These factors were retrospectively determined in 77 patients.
METHODS: Data chart review was performed.
RESULTS: Median follow-up was 102 months (range, 12-366). Surgery was performed on 48 patients, including 9 of the 10 patients with large pancreatic tumors (>/=3 cm). Liver metastases developed in 4 patients (40%) with large pancreatic tumors, in 3 (4.8%) without, and in 1 of the 4 patients with pancreatic tumors of unknown size; all had previously undergone surgery. The only independent factor associated with development of liver metastases identified by multivariate analysis was large pancreatic tumors (risk ratio, 29.0; 95% confidence interval [CI], 3. 2-260.7). Surgery was not selected. The probability of being free of liver metastases in the 63 patients without large pancreatic tumors was 96% (95% CI, 88-100) at 10 and 15 years. Thirteen (16.9%) patients died. The only independent factors of death selected by multivariate analysis were Zollinger-Ellison syndrome diagnosis before 1980 (risk ratio, 8.2; 95% CI, 1.7-40.6) and age at diagnosis (risk ratio/year, 1.08; 95% CI, 1.03-1.14).
CONCLUSIONS: Large pancreatic tumors are predictive of the development of metachronous liver metastases, and surgery does not seem to prevent them.

Entities:  

Mesh:

Year:  1999        PMID: 9922308     DOI: 10.1016/s0016-5085(99)70124-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

Review 1.  Surgery for primary pancreatic neuroendocrine tumors.

Authors:  Jeffrey A Norton
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

2.  Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  Detlef K Bartsch; Volker Fendrich; Peter Langer; Ilhan Celik; Peter H Kann; Matthias Rothmund
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas.

Authors:  Frederic Triponez; David Dosseh; Pierre Goudet; Patrick Cougard; Catherine Bauters; Arnaud Murat; Guillaume Cadiot; Patricia Niccoli-Sire; Jean-Alain Chayvialle; Alain Calender; Charles A G Proye
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 4.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 5.  [Prophylactic pancreas surgery].

Authors:  P Langer; M Rothmund; D K Bartsch
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

Review 6.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

7.  Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy.

Authors:  Robert T Jensen; Jeffrey A Norton
Journal:  Pancreas       Date:  2017 May/Jun       Impact factor: 3.327

Review 8.  Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Fathia Gibril; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2005-05

9.  Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1.

Authors:  Caroline L Lopez; Jens Waldmann; Volker Fendrich; Peter Langer; Peter H Kann; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-07-30       Impact factor: 3.445

10.  Neuroendocrine tumors of the pancreas.

Authors:  Y Van Nieuwenhove; S Vandaele; B Op de Beeck; G Delvaux
Journal:  Surg Endosc       Date:  2003-08-15       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.